EXPECTED VALUE OF PERFECT INFORMATION: ACTIVE LEARNING THROUGH USER-FRIENDLY COMPUTATIONS, DISPLAYS, AND ASIA PACIFIC APPLICATION DISCUSSIONS
|
|
- Lee Quinn
- 6 years ago
- Views:
Transcription
1 EXPECTED VALUE OF PERFECT INFORMATION: ACTIVE LEARNING THROUGH USER-FRIENDLY COMPUTATIONS, DISPLAYS, AND ASIA PACIFIC APPLICATION DISCUSSIONS Jonathan D. Campbell, PhD 1 R Brett McQueen, PhD 1 Jonathan H. Watanabe, PharmD, PhD 2 Nathorn Chaiyakunapruk, PharmD, PhD 3, 1. University of Colorado, Aurora, CO 2. University of California, San Diego, CA 3. Monash University, Kuala Lumpur, Malaysia Workshop Objectives Evidence for cost-effectiveness and value of information Review theory and concepts of value of information Expected Value of Perfect Information (EVPI) active learning Gain understanding through a workshop exercise Display EVPI case Discuss EVPI applications 1
2 What is the question? Is the study population consistent with your own? Are the outcomes for effect size measurement useful? Are you interested in an idealized efficacy analysis to discern the possibility of benefit? Are you interested in an effectiveness analysis that integrates a real-world population? What evidence is missing in the available literature? Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy Turner et al. N Engl J Med 2008;358: What is good evidence? Although studies can arrive at the same conclusion, the methods of each study will differentiate the validity Large Cohort Study of Drug A versus B Users follows patients to determine risk of rare side effect (<1 %) Large Case-Control Study of those with and without the rare side effect (<1 %) to determine probability of exposure Relative Risk of 1.8 Odds Ratio of 1.8 Relative Risk of 1.8 The cohort study would generally be afforded more validity as it compared an exposed and NON-exposed cohort to measure risk excess. The case-control study does not track exposed and non-exposed to event, but only probability of exposure. 2
3 Pyramid of Evidence Sackett DL, Straus SE, Richardson WS, et al. Evidence-based medicine: how to practice and teach EBM. 2nd ed. Edinburgh: Churchill Livingstone, 2000.) Validated and Systematic Scoring of Clinical Trials Studies: Jadad Scores 3 items Maximum of 5 points > 10, 000 Citations Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials Feb;17(1):1-12. PubMed PMID:
4 Validated and Systematic Scoring of Observational Studies: Newcastle-Ottawa Scale Uses a star system on 3 categories: 1. Selection 2. Comparability 3. Outcome or Exposure Outcome for Cohort Studies Exposure for Case-Control Studies Wells G (2011) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available: emiology/oxford.asp. Selection 1. Representativeness of the exposed cohort a) truly representative of the average (describe) in the community b) somewhat representative of the average in the community c) selected group of users eg nurses, volunteers d) no description of the derivation of the cohort 2. Selection of the non exposed cohort a) drawn from the same community as the exposed cohort b) drawn from a different source c) no description of the derivation of the non exposed cohort 3. Ascertainment of exposure to implants a) secure record (eg surgical records) b) structured interview c) written self report d) no description 4. Demonstration that outcome of interest was not present at start of study a) yes b) no 4
5 Comparability 1. Comparability of cohorts on the basis of the design or analysis a) study controls for (select the most important factor) b) study controls for any additional factor (This criteria could be modified to indicate specific control for a second important factor.) 1. Assessment of outcome a) independent blind assessment b) record linkage c) self report d) no description Outcome 2. Was follow up long enough for outcomes to occur a) yes (select an adequate follow up period for outcome of interest) b) no 3. Adequacy of follow up of cohorts a) complete follow up - all subjects accounted for b) subjects lost to follow up unlikely to introduce bias - small number lost - > % (select an adequate %) follow up, or description of those lost) c) follow up rate < % (select an adequate %) and no description of those lost d) no statement 5
6 Adjusted Effect Estimates for Coronary Heart Disease (All Events) (HRT: Estrogen Ever Use) Cohort Studies Selection Comparability Outcome Lauritzen / 83 Wilson / 85 Petitti / 87 Henderson / 91 Lafferty / 94 Folsom / 95 Ettinger / 96 Wolf / Was there some form of sensitivity analysis to provide an uncertainty band? Did they provide a quantitative result of the robustness of their study findings? Did they test other regression models? Did they account for missing data? 6
7 Words of Wisdom As a medical statistician, I am appalled by the large number of irreproducible results in the medical literature. There is a general, and likely correct, perception that this problem is associated with statistical, as opposed to laboratory, research. I am convinced however that results of clinical and epidemiological investigations could become more reproducible if only the investigators would apply more rigorous statistical thinking and adhere more closely to well established principles of the scientific method --Norman Breslow All models are wrong, but some are useful --George Box Theory and Concepts of Value of Information 7
8 Welfare Economics & Bayesian Decision Theory Decision Analytic Model Mean Net benefit Uncertainty in Net Benefit Q1: Adopt Intervention with Present Information? Expected Value of Perfect Information Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. Journal of Health Economics 18 (1999): Q2: Generate Future Evidence? Decision Analytic Model (e.g., Population, intervention, comparator(s), outcome(s), time that best represent disease state) Maximize Social Welfare Function (normative weights included) Mean Net benefit Mean Net Benefit = QALYs*Willingness to pay - Costs Positive analysis Q1: Adopt Intervention with Present Information? Answer = maximum mean net benefit 8
9 Welfare Economics & Bayesian Decision Theory Decision Analytic Model Mean Net benefit Uncertainty in Net Benefit Q1: Adopt Intervention with Present Information? Expected Value of Perfect Information Q2: Generate Future Evidence? Decision Analytic Model Uncertainty analysis (i.e., probabilistic sensitivity analysis) Uncertainty in Net Benefit Decision Uncertainty: probability of error Perfect information (infinite sample) Present information = E(max net benefits for each iteration) max of E(net benefits of all iterations) Expected Value of Perfect Information Upper bound on value of generating future evidence Q2: Generate Future Evidence? 9
10 EVPI Active Learning EVPI Active Learning Definition: E(max net benefits for each iteration) max of E(net benefits of all iterations) Inputs to calculate EVPI: Willingness to pay (how much society is willing to pay for an extra unit of health i.e., QALY) QALYs for each intervention and Monte Carlo iteration Costs for each intervention and Monte Carlo iteration Net benefit = (QALYs)*willingness to pay - Costs 10
11 $25,000 $50,000 $75,000 $100,000 $125,000 $150,000 $175,000 $200,000 $225,000 $250,000 $275,000 $300,000 $325,000 $350,000 $375,000 $400,000 $425,000 $450,000 $475,000 $500,000 EVPI Solution Net Benefit: A Net Benefit: B Max Net Benefit Choose A or B? $ 25, $ - $ 25, A $ 75, $ 50, $ 75, A $ (50,000.00) $ 25, $ 25, B $ 50, $ 50, $ 50, tie $ 25, $ 125, $ 125, B Expected Net Benefit: A Expected Net Benefit: B Expected Max Net Benefit $ 25, $ 50, $ 60, EVPI $ 10, Display EVPI Case $40,000 $35,000 $30,000 $25,000 $20,000 $15,000 $10,000 $5,000 $- EVPI across varying WTP values Willingness to pay (US dollars) 11
12 Reason for a Data Table The EVPI example was based on one willingness-to-pay value What if we wanted to know what EVPI was at $50,000/QALY or $75,000/QALY? To answer this we could manually calculate EVPI for different values of willingness-to-pay Excel can automatically calculate this and record the values in one table using a data table Value of Information Applications 12
13 Examples of Studies using EVPI in Asian counties Accepted ceiling value = 270,000 THB/QALY Future research is not required!!! 13
14 A future research on vaccine efficacy might be a priority. 14
15 VOI Studies in Asian Countries Only a few studies have performed VOI in Asian countries Even though the VOI findings provided clear messages, it was not clear whether the findings have been used for guiding future research direction. There has been no mention of VOI as part of pharmacoeconomics and HTA guidelines in AP region Challenges will be on how to use VOI analysis for research prioritization 15
16 Current State of VOI in Health Care Research Prioritization (PCORI, 2012) Very small number of research informed by VOI studies 16
17 Challenges to use VOI studies for research prioritization (PCORI,2012) Resources Personnel Time Computing resource Scope of VOI Prioritizing across disease areas (Challenging) Prioritizing within a condition (Possible) Prioritizing specific CER (Most common application of VOI) Prioritizing attributes of patient experience common to multiple conditions Challenges to use VOI studies for research prioritization (PCORI,2012) Stakeholder Engagement Lack of familiarity with the methodology Time of VOI Heterogeneity and Equity Effect of Resolving Uncertainty on Patient and Provider Choices 17
18 EXPECTED VALUE OF PERFECT INFORMATION: ACTIVE LEARNING THROUGH USER-FRIENDLY COMPUTATIONS, DISPLAYS, AND ASIA PACIFIC APPLICATION DISCUSSIONS Jonathan D. Campbell, PhD 1 R Brett McQueen, PhD 1 Jonathan H. Watanabe, PharmD, PhD 2 Nathorn Chaiyakunapruk, PharmD, PhD 3, 1. University of Colorado, Aurora, CO 2. University of California, San Diego, CA 3. Monash University, Kuala Lumpur, Malaysia Jon.Campbell@ucdenver.edu; Robert.McQueen@ucdenver.edu; Jhwatanabe@ucsd.edu; nui_nathorn@yahoo.com 18
Value of Information (VOI) Analysis: Principles, Applications and Good Practice Recommendations. ISPOR-AP, Tokyo, Speakers:
Value of Information (VOI) Analysis: Principles, Applications and Good Practice Recommendations ISPOR-AP, Tokyo, 2018 Speakers: Paul Scuffham, PhD, Centre for Applied Health Economics, Menzies Health Institute
More informationFigure 1: Overview of approach for Aim 1
Significance Despite allocating more than $11 billion each year to support clinical research, the system of federal funding for medical research lacks a coordinated approach for allocating resources based
More informationBayesian Statistics in Health Economics
Bayesian Statistics in Health Economics Tony O Hagan University of Sheffield, UK What is Health Economics? Concerned with the question of how to use healthcare resources most efficiently Resources are
More informationLIHS Mini Master Class
Alexandru Nicusor Matei 2013 CC BY-NC-ND 2.0 Value of Information Analysis Alison F. Smith Academic Unit of Health Economics (AUHE) A.f.c.smith University of Leeds 2015. This work is made available for
More informationSchool of Social and Community Medicine
PLEASE DO NOT REPRODUCE Data, Models, and Research: The Role of VoI Methods in Arthritis Nicky J Welton Biologic Therapies in Inflammatory Joint Diseases: Models for Decision Making Arthritis Research
More informationMoving Forward. Adaptive Eligibility Criteria, Alternate Trial Designs, and Subgroup Analysis. Elizabeth Garrett-Mayer, PhD
Moving Forward Adaptive Eligibility Criteria, Alternate Trial Designs, and Subgroup Analysis Elizabeth Garrett-Mayer, PhD Eligibility Trade-offs Broad eligibility Pros: Heterogeneous group Can generalize
More informationIndirect Comparisons in Economic Evaluations: Experience from the Common Drug Review Julie Blouin, Karen M Lee
Indirect Comparisons in Economic Evaluations: Experience from the Common Drug Review Julie Blouin, Karen M Lee 2009 CADTH Symposium April 6, 2009, Ottawa, ON Presentation Outline Background on indirect
More information2014 CLINICAL POLICY UNIT. Dr Vesna Kupresan
2014 CLINICAL POLICY UNIT Dr Vesna Kupresan Healthcare Industry Challenges Medical inflation Cost drivers Aging population Increased utilization of healthcare Growing chronic disease burden Rapid evolution
More informationMark Sculpher, PhD Professor of Health Economics University of York, UK
Using economic modelling to contribute to the prioritisation and design and clinical trials: ready for prime time Mark Sculpher, PhD Professor of Health Economics University of York, UK Clinical Trials
More informationMarkov Model in Health Care
Markov Model in Health Care Septiara Putri Center for Health Economics and Policy Studies 4/10/2015 1 Objectives Introduce and familiarize participants with basic Markov modeling for economic evaluation
More informationThe challenges of preparing evidence for decision modelling. Marta Soares Centre for Health Economics, University of York
The challenges of preparing evidence for decision modelling Marta Soares Centre for Health Economics, University of York MRC biostats 10/02/2015 Overview Context Overview of decision modelling Overview
More informationFacilitating Antibacterial Drug Development: Bayesian vs Frequentist Methods
Facilitating Antibacterial Drug Development: Bayesian vs Frequentist Methods Scott S. Emerson, M.D., Ph.D. Professor of Biostatistics University of Washington The Brookings Institution May 9, 2010 First:
More informationSentinel Journey from Safety Question to Regulatory Action. Rima Izem, PhD
Sentinel Journey from Safety Question to Regulatory Action Rima Izem, PhD rima.izem@fda.hhs.gov Food and Drug Administration Center for Drug Evaluation and Research Division of Biometrics 7 1 Disclaimer
More informationStudy population The study population comprised patients undergoing major hip or knee surgery.
Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients Dranitsaris G, Kahn S R, Stumpo C, Paton T W, Martineau J, Smith R,
More informationAn Introduction to Flexible Adaptive Designs
An Introduction to Flexible Adaptive Designs Roger J. Lewis, MD, PhD Department of Emergency Medicine Harbor-UCLA Medical Center David Geffen School of Medicine at UCLA Los Angeles Biomedical Research
More informationField trial with veterinary vaccine
١ Field trial with veterinary vaccine Saeedeh Forghani,, M.D. Clinical Trial and Ethics Department Human Health Management Deputy of Quality Assurance 89/4/2 ٢ ٣ Introduction: The efficacy and safety shall
More informationCUSTOM DECISION SUPPORT, LLC Telephone (831) Pharmaceutical Pricing Research
CUSTOM DECISION SUPPORT, LLC Telephone (831) 854-2256 gene@lieb.com http://www.lieb.com Pharmaceutical Pricing Research Custom Decision Support, LLC (CDS) provides pricing analytic services to both commercial
More informationIntroduction to the Design and Evaluation of Group Sequential
SSCR ntroduction to the Design and Evaluation of Group Sequential Session 1 - Scientific Setting and mplications Presented July 27, 2016 Daniel L. Gillen Department of Statistics University of California,
More informationPharmacogenomics and Health Policy
Pharmacogenomics and Health Policy Amalia M. Issa, PhD, MPH Founding Director, Program in Personalized Medicine & Targeted Therapeutics Professor and Chair Department of Health Policy and Public Health
More informationCost-effectiveness and cost-utility analysis accompanying Cancer Clinical trials. NCIC CTG New Investigators Workshop
Cost-effectiveness and cost-utility analysis accompanying Cancer Clinical trials NCIC CTG New Investigators Workshop Keyue Ding, PhD. NCIC Clinical Trials Group Dept. of Public Health Sciences Queen s
More informationCrowe Critical Appraisal Tool (CCAT) User Guide
Crowe Critical Appraisal Tool (CCAT) User Guide Version 1.4 (19 November 2013) Use with the CCAT Form version 1.4 only Michael Crowe, PhD michael.crowe@my.jcu.edu.au This work is licensed under the Creative
More informationCASP Checklist: 12 questions to help you make sense of an Economic Evaluation
CASP Checklist: 12 questions to help you make sense of an Economic Evaluation How to use this appraisal tool: Three broad issues need to be considered when appraising an economic evaluation study: Is the
More informationSystematic Reviews: How Accurate Are They and Can We Do Better?
Systematic Reviews: How Accurate Are They and Can We Do Better? Authors: Gerald Borok, PhD, MPH Todd Feinman, MD Iris Tam, PharmD Gerald M. Borok, PhD, MPH Senior Director, Client Solutions Doctor Evidence,
More information8. Clinical Trial Assessment Phase II
8. Clinical Trial Assessment Phase II Junko Sato, PhD Office of New Drug I, PMDA Disclaimer: The information within this presentation is based on the presenter s expertise and experience, and represents
More informationValue Assessment: Building Payercentric value propositions to inform decision-making
Value Assessment: Building Payercentric value propositions to inform decision-making Aris Angelis and Panos Kanavos Medical Technology Research Group, LSE Health Advance-HTA dissemination workshop, Santiago,
More informationDraft agreed by Scientific Advice Working Party 5 September Adopted by CHMP for release for consultation 19 September
23 January 2014 EMA/CHMP/SAWP/757052/2013 Committee for Medicinal Products for Human Use (CHMP) Qualification Opinion of MCP-Mod as an efficient statistical methodology for model-based design and analysis
More informationDraft Guidance for Industry Development and Use of Risk Minimization Action Plans
Draft Guidance for Industry Development and Use of Risk Minimization Action Plans Docket Number [2004D-0188] Submitted to the U.S. Department of Health and Human Services Food and Drug Administration Center
More informationEvolve or die: the urgent need to streamline randomized trials
Evolve or die: the urgent need to streamline randomized trials Rory Collins British Heart Foundation Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU),
More informationHTA Principles Survey Questionnaire
I. Introduction This survey aims to inform health care decision makers in their rational and efficacious applications of health technology assessment (HTA) in Asia, while adhering to key established benchmarks.
More informationComparative Effectiveness Research and Personalized Medicine: Policy, Science and Business. Setting the Stage. October 28, 2009 Washington, DC
Comparative Effectiveness Research and Personalized Medicine: Policy, Science and Business Setting the Stage October 28, 2009 Washington, DC Clifford Goodman, PhD Vice President clifford.goodman@lewin.com
More informationThe Right Data for the Right Questions:
The Right Data for the Right Questions: Evidentiary Needs as a Guide to Data Source Selection David Thompson, PhD Senior Vice President Louise Parmenter, PhD Global Head of Operations Real-World & Late
More informationKenneth J. Wilkins & Elizabeth C. Wright Biostatistics Program, Office of the Director NIDDK/NIH
Challenges in assessing journal authors' awareness of emerging standards for handling missing data, with illustrations from a focused review of Hepatitis C trials Society for Clinical Trials 35 th Annual
More informationClinical Trials Augmented by Simulation and Bench Testing. Mock Submission Informational Meeting
1 Clinical Trials Augmented by Simulation and Bench Testing Mock Submission Informational Meeting 2 Outline Background of MDIC and working group Virtual patients what are they? Statistical framework how
More informationTowards an Interventions Assessment Model for E. coli O157:H7 in Leafy Greens
Towards an Interventions Assessment Model for E. coli O157:H7 in Leafy Greens Applying the Conceptual Framework Michael Batz University of Maryland School of Medicine mbatz@epi.umaryland.edu E. coli O157:H7
More informationThe Hexagon: An Exploration Tool. Hexagon Discussion & Analysis Tool Instructions NIRN NATIONAL IMPLEMENTATION RESEARCH NETWORK 2018 NIRN
The Hexagon: An Exploration Tool Hexagon Discussion & Analysis Tool Instructions NIRN NATIONAL IMPLEMENTATION RESEARCH NETWORK 2018 NIRN 2018 NIRN University of North Carolina at Chapel Hill Metz, A. &
More informationPublications for payors: what evidence do they really need? Ian Pickles, Strategy Consultant, Complete Clarity
Publications for payors: what evidence do they really need? Ian Pickles, Strategy Consultant, Complete Clarity OBJECTIVES FOR THE SESSION To be able to build payer evidence requirements into publication
More informationIntegrating Existing Reviews into the CADTH Optimal Use Project on HPV Testing for Primary Cervical Cancer Screening
Integrating Existing Reviews into the CADTH Optimal Use Project on HPV Testing for Primary Cervical Cancer Screening Rationale for Integrating Existing Reviews As part of the a priori planned methods for
More informationPersonalized Medicine: Will There be a Right Time to Implement?
Pharmacogenomics based personalized medicine: Are the standards of evidence requirements different from standards for Clinical-Based Personalized Medicine? Devender S. Dhanda MS MBA, Greg F. Guzauskas
More informationThe Hexagon: An Exploration Tool. Hexagon Discussion & Analysis Tool Instructions NIRN NATIONAL IMPLEMENTATION RESEARCH NETWORK 2018 NIRN
The Hexagon: An Exploration Tool Hexagon Discussion & Analysis Tool Instructions NIRN NATIONAL IMPLEMENTATION RESEARCH NETWORK 2018 NIRN 2018 NIRN University of North Carolina at Chapel Hill Metz, A. &
More informationRecent publications & Announcements
Recent publications & Announcements HLP Seminar October 2018 https://rdcu.be/8vz2 2 https://rdcu.be/8tlf 3 https://t.co/resz5nfjlt 4 Social media mining for birth defects research: A rule-based, bootstrapping
More informationTo begin from the beginning
POST-AUTHORISATION STUDIES IN EUROPE: BRIDGING THE GAP BETWEEN REGULATORY AND HEALTH TECHNOLOGY ASSESSMENT (HTA) STAKEHOLDER NEEDS BY BETTER DESIGN OF STUDIES Massoud Toussi Epidemiology, Europe Real World
More informationHTA methodology at HIQA. Conor Teljeur
HTA methodology at HIQA Conor Teljeur What is HTA? Health technology assessment (HTA) is a multidisciplinary process that summarises information about the medical, social, economic and ethical issues related
More informationUse of RWE in a regulatory context: issues and examples. Rob Hemmings, MHRA
Use of RWE in a regulatory context: issues and examples Rob Hemmings, MHRA Disclaimer I don t particularly like the terms real world data, real world evidence. To be more precise, I will discuss data generated
More informationThe Journey of a Knowledge Management Fellow
The Journey of a Knowledge Management Fellow Rachel Cooke Acting Lead for Libraries & Knowledge National Health Service, East of England & Lead for the NHS Evidence - Knowledge Management Special Collection
More informationSyllabus for M.Pharm Clinical Research Semester II
Syllabus for M.Pharm Clinical Research Semester II Clinical Research Methodology Paper I MPCR 201 T Scope After Completion of the course students should be able to understand various practical aspects
More informationPh.D. Defense: Resource Allocation Optimization in the Smart Grid and High-performance Computing Tim Hansen
Ph.D. Defense: Resource Allocation Optimization in the Smart Grid and High-performance Computing Tim Hansen Department of Electrical and Computer Engineering Colorado State University Fort Collins, Colorado,
More informationTechnology as a driver of medical progress and access: the role of universities
WHO, WIPO, WTO Joint Technical Symposium on Sustainable Development Goals: Innovative technologies to promote healthy lives and well-being February 26th 2018 Technology as a driver of medical progress
More informationPARTNERSHIP IN APPLIED COMPARATIVE EFFECTIVENESS RESEARCH SCIENCE (PACES)
PARTNERSHIP IN APPLIED COMPARATIVE EFFECTIVENESS RESEARCH SCIENCE (PACES) Jodi Segal, MD, MPH Associate Professor of Medicine, Epidemiology, Health Policy and Management Johns Hopkins University Objectives
More informationAdvancing Research by Publishing Research Protocols and Negative Studies
Advancing Research by Publishing Research Protocols and Negative Studies Riaz Agha Balliol College, University of Oxford and Department of Plastic Surgery, Guy s and St. Thomas NHS Foundation Trust editor@journal-surgery.com
More informationValue of information analysis optimizing future trial design from a pilot study on. catheter securement devices
1 Value of information analysis optimizing future trial design from a pilot study on catheter securement devices Haitham W Tuffaha *1,2, Heather Reynolds 3,4, Louisa Gordon 1,2, Claire M Rickard 3,4, Paul
More informationTÁMOP /2/A/KMR
HEALTH ECONOMICS HEALTH ECONOMICS Sponsored by a Grant TÁMOP-4.1.2-08/2/A/KMR-2009-0041 Course Material Developed by Department of Economics, Faculty of Social Sciences, Eötvös Loránd University Budapest
More informationPotential Steps in Active Surveillance
Background The Sentinel System will augment FDA s postmarket safety assessment capabilities by enhancing its capacity to conduct active surveillance at the population level. Conducting active surveillance
More information2/11/2014. Key Sources of Uncertainty in the Assessment of Benefits and Risks of Pharmaceuticals and Associated Challenges. Disclaimer.
Key Sources of Uncertainty in the Assessment of Benefits and Risks of Pharmaceuticals and Associated Challenges Institute of Medicine Workshop: Characterizing and Communicating Uncertainty in the Assessment
More informationOpportunities in the Health Care Practice at Analysis Group
Opportunities in the Health Care Practice at Analysis Group Johns Hopkins Blomberg School of Public Health October 3, 2016 You Will Learn Today: Who the Analysis Group is What our Health Care Practice
More informationIntroduction to Results-Based M&E and Impact Evaluation
Introduction to Results-Based M&E and Impact Evaluation Philip Davies April 17, 2007 World Bank Workshop Using Monitoring and Evaluation for Better Education Policy, Planning and Results Bali, Indonesia
More informationNICE Guidelines: A Methodological Basis for Decision Making. Rod Taylor MSc, PhD Dept of Public Health & Epidemiology University of Birmingham
NICE Guidelines: A Methodological Basis for Decision Making Rod Taylor MSc, PhD Dept of Public Health & Epidemiology University of Birmingham Pre Meeting Symposium - ISPOR Annual Conference Washington
More informationISPOR BOOK OF TERMS. Editors MARC L. BERGER, MD KERSTIN BINGEFORS, PhD EDWIN C. HEDBLOM, PharmD CHRIS L. PASHOS, PhD GEORGE W.
HEALTH GARE COST, QUALITY, AND OUTCOMES ISPOR BOOK OF TERMS Editors MARC L. BERGER, MD KERSTIN BINGEFORS, PhD EDWIN C. HEDBLOM, PharmD CHRIS L. PASHOS, PhD GEORGE W. TORRANCE, PhD Managing Editor MARILYN
More informationEvidence-based medicine competencies
Oregon Health & Science University OHSU Digital Commons Scholar Archive December 2007 Evidence-based medicine competencies Misbah K. Keen Follow this and additional works at: http://digitalcommons.ohsu.edu/etd
More informationEvaluation of existing methods for safety signal identification for the Sentinel Initiative
Evaluation of existing methods for safety signal identification for the Sentinel Initiative Jennifer C. Nelson Biostatistics Unit Group Health Research Institute Department of Biostatistics University
More informationLife Cycle Assessment A product-oriented method for sustainability analysis. UNEP LCA Training Kit Module f Interpretation 1
Life Cycle Assessment A product-oriented method for sustainability analysis UNEP LCA Training Kit Module f Interpretation 1 ISO 14040 framework Life cycle assessment framework Goal and scope definition
More informationMethods for health economic evaluations
GUIDELINE Methods for health economic evaluations - A guideline based on current practices in Europe May 2015 Copyright EUnetHTA 2013. All Rights Reserved. No part of this document may be reproduced without
More informationHealth Technology Assessment and Pragmatic Controlled Trials
Health Technology Assessment and Pragmatic Controlled Trials 6 th Annual Meeting of Health Technology Assessment International Singapore june 2009 Associate Professor Eva Draborg Institute of Public Health
More informationNuts & Bolts of Clinical Trials, DSMBs, Event Committees, Core Labs and Data Standards
Nuts & Bolts of Clinical Trials, DSMBs, Event Committees, Core Labs and Data Standards Ron Waksman, MD Professor of Medicine, Georgetown University Associate Chief of Cardiology, Washington Hospital Center
More informationEvaluation Tools for COMPUS
Evaluation Tools for COMPUS Background The Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) identifies, evaluates, promotes and facilitates best practices in drug prescribing and
More informationBenefit Cost Analysis Stakeholder Survey Results
Benefit Cost Analysis Stakeholder Survey Results October 2017 Prepared by: Cristina Munk, Lisa A. Robinson, and James K. Hammitt Center for Health Decision Science Harvard T.H. Chan School of Public Health
More informationAppendix 5: Details of statistical methods in the CRP CHD Genetics Collaboration (CCGC) [posted as supplied by
Appendix 5: Details of statistical methods in the CRP CHD Genetics Collaboration (CCGC) [posted as supplied by author] Statistical methods: All hypothesis tests were conducted using two-sided P-values
More informationNurturing the Clinical Research Leaders of Tomorrow
GOOD REGULATORY SCIENCE IN ASIA/PACIFIC: PART 2 365 Nurturing the Clinical Research Leaders of Tomorrow Feng-Pin Chuang, MD Tri-Service General Hospital, National Defense Medical Center, Wing-Kai Chan,
More informationAccess, Affordability and Innovation Focus on High Cost Medicines: Facts and Potential Options
Access, Affordability and Innovation Focus on High Cost Medicines: Facts and Potential Options Ashoke Bhattacharjya, PhD Robert E Campbell Pharmaceutical Seminar Rutgers Business School Feb 15, 2017 1
More informationTrial oversight SOP for HEY-sponsored CTIMPs
R&D Department Trial oversight SOP for HEY-sponsored CTIMPs Hull And East Yorkshire Hospitals NHS Trust 2010 All Rights Reserved No part of this document may be reproduced, stored in a retrieval system
More informationPROPENSITY SCORE MATCHING A PRACTICAL TUTORIAL
PROPENSITY SCORE MATCHING A PRACTICAL TUTORIAL Cody Chiuzan, PhD Biostatistics, Epidemiology and Research Design (BERD) Lecture March 19, 2018 1 Outline Experimental vs Non-Experimental Study WHEN and
More informationStatistical Competencies for Clinical & Translational Science: Evolution in Action
Statistical Competencies for Clinical & Translational Science: Evolution in Action Felicity Enders, PhD Association of Clinical and Translational Statisticians Annual Meeting Boston, MA, August 2, 2014
More informationMathematical Modeling of Tuberculosis
Mathematical Modeling of Tuberculosis An introduction Olivia Oxlade, PhD olivia.oxlade@mcgill.ca Advanced TB diagnostic Research Course: Montreal July 5 8, 2011 Objectives of Session Consider the reasons
More informationSection I: Pharmaceuticals and Medical Devices
SUPPLEMENT on HEALTHCARE INNOVATION Visionary Goals and Recommendations 51th Japan-U.S. Business Conference Japan-U.S. Business Council / U.S.-Japan Business Council November 14, 2014 The R&D-based pharmaceutical
More informationYale University. Open Data Access Project
Open Data Access Project A Model for Dissemination and Independent Analysis of Clinical Trial Program Data Funded by a contract with Medtronic, Inc. Session Objectives Why do we need to promote data sharing?
More informationWhite Paper January 2017 META-ANALYSIS FOR HEALTH TECHNOLOGY SUBMISSIONS WORLDWIDE: A REPORT CHECKLIST FOR BEST PRACTICE. Sarah Batson, Neil Webb
05 NETWORK White Paper January 2017 META-ANALYSIS FOR HEALTH TECHNOLOGY SUBMISSIONS WORLDWIDE: A REPORT CHECKLIST FOR BEST PRACTICE Sarah Batson, Neil Webb Network meta-analysis (NMA) is an accepted statistical
More informationBIOSTATISTICS AND MEDICAL INFORMATICS (B M I)
Biostatistics and Medical Informatics (B M I) 1 BIOSTATISTICS AND MEDICAL INFORMATICS (B M I) B M I/POP HLTH 451 INTRODUCTION TO SAS PROGRAMMING FOR 2 credits. Use of the SAS programming language for the
More informationImpact Evaluation. Some Highlights from The Toolkit For The Evaluation of Financial Capability Programs in LMIC
Impact Evaluation Some Highlights from The Toolkit For The Evaluation of Financial Capability Programs in LMIC World Bank Dissemination Workshop, New Delhi March 2013 What is the Toolkit? Russia Trust
More informationComparative Effectiveness Research. Informing Public and Private Payer Decision-Making Brian Sweet, Chief Pharmacy Officer June 24, 2010
Comparative Effectiveness Research Informing Public and Private Payer Decision-Making Brian Sweet, Chief Pharmacy Officer June 24, 2010 How Evidence Begins No Evidence Beginning of Human Testing FDA Approval
More informationAdvancing Methods of Health Technology Assessment for medical devices: the EU MedTecHTA project
Advancing Methods of Health Technology Assessment for medical devices: the EU MedTecHTA project Rosanna Tarricone, PhD Director CERGAS Bocconi University, Milan Project Funded under FP7 Funded - HEALTH
More informationValuing informal care an overview. Bernard van den Berg
Valuing informal care an overview Bernard van den Berg Email: bernard.vandenberg@york.ac.uk Valuing informal care: Today s objectives 1. Give an overview of methods that have been proposed/used to value
More informationAppropriate Control Strategies Eliminate the Need for Redundant Testing of Pharmaceutical Products
Date: April 23, 2012 Appropriate Control Strategies Eliminate the Need for Redundant Testing of Pharmaceutical Products Key Messages Importation quality control testing for pharmaceutical, biological/biotechnology
More informationInternational Program for Development Evaluation Training (IPDET)
The World Bank Group Carleton University IOB/Ministry of Foreign Affairs, Netherlands International Program for Development Evaluation Training (IPDET) Building Skills to Evaluate Development Interventions
More informationNDA Advisory Services Ltd
Declaration of Interest statement: Paul Chamberlain has received Consulting fees from different companies in respect of strategic and operational advice relating to biopharmaceutical development; he is
More informationUtilizing Optimization Techniques to Enhance Cost and Schedule Risk Analysis
1 Utilizing Optimization Techniques to Enhance Cost and Schedule Risk Analysis Colin Smith, Brandon Herzog SCEA 2012 2 Table of Contents Introduction to Optimization Optimization and Uncertainty Analysis
More informationGuidelines for the Economic Evaluation of Health Technologies in Ireland
Guidelines for the Economic Evaluation of Health Technologies in Ireland 2018 1 About the The (HIQA) is an independent authority established to drive high-quality and safe care for people using our health
More informationR&D Performance Management
R&D Performance Management What is in for me to drive the biotech opportunity? Gerd Grimm Reutlingen, December 2015 Agenda 1. What is R&D Performance Management? 2. A way of thinking about decisions rules
More informationIntroduction to Economic Evaluations
Introduction to Economic Evaluations Marcelo Coca Perraillon University of Colorado Anschutz Medical Campus Cost-Effectiveness Analysis HSMP 6609 2016 1 / 36 Outline Agenda for today: The big picture -
More informationAnalyzing the Scientific Literature: Pitfalls and Reproducibility
Analyzing the Scientific Literature: Pitfalls and Reproducibility Samuel M. Cohen, M.D., Ph.D. Department of Pathology and Microbiology University of Nebraska Medical Center Omaha, NE 68198-3135, USA scohen@unmc.edu
More informationWeighted- Student. Using school-level dynamic weighting for a more equitable funding allocation. Funding 2.0
Weighted- Student Funding Using school-level dynamic weighting for a more equitable funding allocation. 2.0 Weighted- Student Funding 2.0 Using school-level dynamic weighting for a more equitable funding
More informationEMA Adaptive licensing: a tool concept for accelerated access to innovative medicines? Rob Hemmings, MHRA
EMA Adaptive licensing: a tool concept for accelerated access to innovative medicines? Rob Hemmings, MHRA Slides largely re-produced from a previous EMA presentations to (DIA, Paris; STAMP, Brussels).
More informationBayesian Submissions to FDA and the Evidentiary Standard for Effectiveness: the CDRH Experience
Bayesian Submissions to FDA and the Evidentiary Standard for Effectiveness: the CDRH Experience Gregory Campbell, Ph.D. President, GCStat Consulting, LLC Former Director, Division of Biostatistics Center
More informationTeaching Vaccine Economics Everywhere Syllabus Economic Evaluation Module
Teaching Vaccine Economics Everywhere Syllabus Economic Evaluation Module The demand and cost of health services is steadily increasing due to population growth, rising income and expectations, higher
More informationCompetencies Checklist for CE. Tier 1 Core Public Health Competencies Checklist
Competencies Checklist for CE Student Name: Area of Concentration: Project Title: Tier 1 Core Public Health Competencies Checklist Domain #1: Analytic/Assessment Skills Describes factors affecting the
More informationImpact Evaluation Objectives and Design
Impact Evaluation Objectives and Design Laura B. Rawlings World Bank Second International Workshop on Conditional Cash Transfer Programs Sao Paulo, Brazil - April 2004 Outline Monitoring vs. Evaluation
More informationWhy do clinicians love 3+3? How do we help them de-love it? How to properly model late onset toxicity?
Why do clinicians love 3+3? How do we help them de-love it? How to properly model late onset toxicity? How to use big data in drug development and dose selection? How to design combination dose-finding
More informationNot Happy with Pharmacy Research? Let s Build a List of Research Priorities Together!
Not Happy with Pharmacy Research? Let s Build a List of Research Priorities Together! AMCP Research Prioritization Initiative (RPI) Disclaimer Organizations may not re use material presented at this AMCP
More informationNICE methods of technology appraisal
NICE methods of technology appraisal Zoe Garrett Senior Technical Adviser, Centre for Health Technology Evaluation National Institute for Health and Care Excellence (NICE) Contents Function of NICE Work
More informationThe Nottingham eprints service makes this work by researchers of the University of Nottingham available open access under the following conditions.
Pecchia, Leandro and Craven, Michael P. (2013) Early stage health technology assessment (HTA) of biomedical devices: the MATCH experience. In: World Congress on Medical Physics and Biomedical Engineering,
More informationUsing Multiple Criteria Decision Analysis (MCDA) in the context of HTA: an experimental case study on metastatic colorectal cancer
Using Multiple Criteria Decision Analysis (MCDA) in the context of HTA: an experimental case study on metastatic colorectal cancer Aris Angelis and Panos Kanavos Advance HTA Conference, London, November
More informationData Sharing and Models in Pre(Non)- Competitive Space in Addressing Unmet Medical Needs. Critical Path Institute s Alzheimers Drug Development Tool
Data Sharing and Models in Pre(Non)- Competitive Space in Addressing Unmet Medical Needs Critical Path Institute s Alzheimers Drug Development Tool Vikram Sinha, PhD Director, Division of Pharmacometrics
More information